Literature DB >> 2127899

Venoconstrictor responses to dihydroergocristine and dihydroergotamine: evidence for the involvement of 5-HT1 like receptors.

E Müller-Schweinitzer1.   

Abstract

Dihydroergocristine (DHEC) and dihydroergotamine (DHE) were investigated on canine saphenous veins in vivo and on canine saphenous veins and basilar arteries in vitro. Following local i.v. infusion in vivo, the venoconstrictor response to DHEC was about 30% weaker than that produced by DHE. When administered orally, however, both ergot alkaloids elicited similar venoconstrictor effects. In vitro maximal contractile responses to DHEC and DHE of basilar arteries were only 20-30% of those produced by 5-HT, whereas in saphenous veins both DHEC and DHE elicited similar maximal effects as those observed with 5-HT. In saphenous veins, methiothepin antagonized venoconstrictor responses to 5-HT, DHEC, and DHE within the same concentration range, being significantly less potent when tested against noradrenaline. The reverse was true for yohimbine, which was significantly more potent against noradrenaline than against 5-HT, DHEC, and DHE. It is suggested that the venoconstrictor responses to both DHEC and DHE are mediated through 5-HT1-like receptors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2127899     DOI: 10.1007/bf02026491

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  21 in total

1.  Characterization of 5-HT receptors mediating contraction of canine and primate basilar artery by use of GR43175, a selective 5-HT1-like receptor agonist.

Authors:  H E Connor; W Feniuk; P P Humphrey
Journal:  Br J Pharmacol       Date:  1989-02       Impact factor: 8.739

2.  The specific activity of retained and released norepinephrine in dog saphenous vein prelabeled with radiolabeled norepinephrine.

Authors:  D K Rorie; S M Muldoon; G M Tyce
Journal:  Life Sci       Date:  1980-03-03       Impact factor: 5.037

3.  Evidence for two populations of 5-hydroxytryptamine receptors in dog basilar artery.

Authors:  M Frenken
Journal:  J Pharmacol Exp Ther       Date:  1989-07       Impact factor: 4.030

4.  In vitro studies on the duration of action of dihydroergotamine.

Authors:  E Müller-Schweinitzer
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1980

5.  The recording of venous compliance in the conscious dog: a method for the assessment of venoconstrictor agents.

Authors:  E Müller-Schweinitzer
Journal:  J Pharmacol Methods       Date:  1984-08

6.  Evidence for mediation by 5-HT2 receptors of 5-hydroxytryptamine-induced contraction of canine basilar artery.

Authors:  E Müller-Schweinitzer; G Engel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-12       Impact factor: 3.000

7.  Alpha-adrenoceptors, 5-hydroxytryptamine receptors and the action of dihydroergotamine in human venous preparations obtained during saphenectomy procedures for varicose veins.

Authors:  E Müller-Schweinitzer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-10       Impact factor: 3.000

8.  [Hypertension therapy with Briserin: what role do dihydroergocristine components play?].

Authors:  F Schardt; P Polzien
Journal:  Med Klin       Date:  1981-12-18

9.  A comparison of 5-hydroxytryptamine receptors mediating contraction in rabbit aorta and dog saphenous vein: evidence for different receptor types obtained by use of selective agonists and antagonists.

Authors:  W Feniuk; P P Humphrey; M J Perren; A D Watts
Journal:  Br J Pharmacol       Date:  1985-11       Impact factor: 8.739

10.  Pharmacological studies on frozen stored canine saphenous veins and basilar arteries.

Authors:  E Müller-Schweinitzer; C Tapparelli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-01       Impact factor: 3.000

View more
  4 in total

1.  Endothelial 5-HT receptors mediate relaxation of porcine pulmonary arteries in response to ergotamine and dihydroergotamine.

Authors:  E Glusa; A Roos
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

Review 2.  Acute treatment of migraines.

Authors:  Arnaldo N Da Silva; Stewart J Tepper
Journal:  CNS Drugs       Date:  2012-10-01       Impact factor: 5.749

Review 3.  Migraine Treatment: Current Acute Medications and Their Potential Mechanisms of Action.

Authors:  Jonathan Jia Yuan Ong; Milena De Felice
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

4.  DHE repression of ATP-mediated sensitization of trigeminal ganglion neurons.

Authors:  Caleb G Masterson; Paul L Durham
Journal:  Headache       Date:  2010-10       Impact factor: 5.887

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.